Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Infectious Diseases

Fitness & Nutrition

COVID-19

Pharmaceutical

Biotechnology

Meiji Seika Pharma Co., Ltd.

More Like This

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery

Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing

Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI

Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

Left: Keitaro Iwaki, President & Representative Director, SPERA PHARMA; Right: Jun Kawakami, President & CEO, Rigaku

Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development